ALPMY News and Press, Astellas Pharma Inc. ADR From 09/27/21

Most companies in the pharmaceutical space have been the subject of immense investor attention since the onset of the COVID-19 pandemic last year. The demand for their products and services is expected to increase in the coming months due to an aging population and increasing demand for thera...

Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer - Enfortumab vedotin is the first and only antibody-drug conjugate (ADC) approved in Japan for patients with advanced urothelial cancer - PR Newswire TOKYO and BOTHELL, Wash....

Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ Trial in Oral Session at The North American Menopause Society 2021 Annual Meeting Astellas' investigational non-hormonal treatment demonstrates reduction in frequency and severity of moderate to se...

Astellas and MBC BioLabs Announce Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators PR ...

Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study Late-breaking abstract to be presented September 18 during European Society for Medical Oncology Congress 2021 PR ...

Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy PR Newswire TOKYO , Sept. 14, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasuka...

Astellas Pharma (OTCPK:ALPMF) has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy (XLMTM). This decision follows the reporting of a recent serious adverse event (SAE) in a study part...

Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy PR Newswire TOKYO , September 1, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") a...

Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification ...

Last month, the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) denied AstraZeneca (NASDAQ: AZN) and FibroGen 's (NASDAQ: FGEN) drug roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD)....